Northeast Investment Management Decreases Stock Holdings in Johnson & Johnson $JNJ

Northeast Investment Management reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 174,167 shares of the company’s stock after selling 1,789 shares during the period. Northeast Investment Management’s holdings in Johnson & Johnson were worth $26,604,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of JNJ. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Wealth Group Ltd. purchased a new stake in Johnson & Johnson in the first quarter valued at $218,000. GAMMA Investing LLC lifted its position in Johnson & Johnson by 48.0% in the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock valued at $7,215,000 after acquiring an additional 14,118 shares during the last quarter. Monte Financial Group LLC lifted its position in Johnson & Johnson by 1.3% in the first quarter. Monte Financial Group LLC now owns 36,636 shares of the company’s stock valued at $5,769,000 after acquiring an additional 464 shares during the last quarter. Finally, Weaver Capital Management LLC increased its stake in Johnson & Johnson by 30.9% in the first quarter. Weaver Capital Management LLC now owns 12,261 shares of the company’s stock valued at $2,033,000 after purchasing an additional 2,891 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Sanford C. Bernstein lifted their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Royal Bank Of Canada restated an “outperform” rating and issued a $209.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 10th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Weiss Ratings upgraded shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $200.06.

Johnson & Johnson Stock Up 0.3%

JNJ stock opened at $193.78 on Tuesday. The company has a market cap of $466.68 billion, a P/E ratio of 18.70, a P/E/G ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The company’s 50-day moving average price is $180.89 and its 200 day moving average price is $165.18. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The firm had revenue of $24.02 billion for the quarter. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.